发明名称 |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
摘要 |
The present disclosure provides methods of increasing the level of a polypeptide of interest in a mammalian subject by administering a polynucleotide having one or more chemical modifications and a Protein:Cytokine ratio of greater than 100. |
申请公布号 |
US9428535(B2) |
申请公布日期 |
2016.08.30 |
申请号 |
US201213644072 |
申请日期 |
2012.10.03 |
申请人 |
Moderna Therapeutics, Inc. |
发明人 |
de Fougerolles Antonin;Roy Atanu;Schrum Jason P.;Siddiqi Suhaib;Hatala Paul;Bancel Stephane |
分类号 |
C12N15/11;C07H21/02;C12N15/67;A61K48/00 |
主分类号 |
C12N15/11 |
代理机构 |
Clark & Elbing LLP |
代理人 |
Clark & Elbing LLP |
主权项 |
1. A method of expressing a polypeptide of interest in a mammalian subject comprising administering to said subject an isolated mRNA comprising:
(a) a sequence of n number of linked nucleosides, (b) a 5′ UTR, (c) a 3′ UTR, and (d) at least one 5′ cap structure, wherein said isolated mRNA is fully modified with 1-methylpseudouridine, wherein said isolated mRNA, when administered to peripheral blood mononuclear cells provides Protein:Cytokine (P:C) ratios of greater than 100 for TNF-alpha and greater than 100 for IFN-alpha after about eighteen or more hours, and wherein said P:C ratios are higher than those of a corresponding mRNA comprising pseudouridine in place of 1-methylpseudouridine. |
地址 |
Cambridge MA US |